In vivo administration of PACAP reduces neuronal loss in the substantia nigra in acute models of Parkinson’s Disease: 6-Hydroxydopamine and MPTP treatment (Reglodi et al. 2004, 2006; Wang et al. 2008). This evidence concerns the gene ADCYAP1 and Parkinson disease.